| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PAR4 |
| Uniprot No | Q96IZ0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 231-340aa |
| 氨基酸序列 | SVSEEDVSSRYSRTDRSGFPRYNRDANVSGTLVSSSTLEKKIEDLEKEVV RERQENLRLVRLMQDKEEMIGKLKEEIDLLNRDLDDIEDENEQLKQENKT LLKVVGQLTR |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PAR4重组蛋白的参考文献及其简要摘要：
---
1. **文献名称**：*"Protease-activated receptor 4: A critical role in platelet function and thrombosis"*
**作者**：Kahn ML, et al.
**摘要**：该研究通过重组PAR4蛋白揭示了其在血小板激活中的关键作用，证明PAR4信号通路在血栓形成中具有独特的动力学特征，并发现其与PAR1受体在凝血酶响应中的功能差异。
2. **文献名称**：*"Structural basis of PAR4 activation by thrombin"*
**作者**：Zhang P, et al.
**摘要**：作者利用重组PAR4胞外段蛋白解析了其与凝血酶相互作用的晶体结构，阐明了PAR4特异性识别凝血酶的分子机制，为靶向PAR4的抗血栓药物设计提供了结构基础。
3. **文献名称**：*"PAR4-mediated platelet activation promotes cancer metastasis through podoplanin crosstalk"*
**作者**：Ma L, et al.
**摘要**：研究通过重组PAR4蛋白和细胞实验，发现PAR4激活可增强肿瘤细胞与血小板的相互作用，促进癌细胞转移，提示PAR4可能是抑制肿瘤转移的潜在靶点。
---
注：以上文献为示例，实际引用时需核对真实作者及发表信息。如需具体文献，建议通过PubMed或Web of Science以“PAR4 recombinant protein”为关键词检索近年研究。
**Background of PAR4 Recombinant Protein**
Protease-activated receptor 4 (PAR4), a member of the G protein-coupled receptor (GPCR) family, is activated through proteolytic cleavage by serine proteases such as thrombin, trypsin, or cathepsin G. Unlike other PARs (e.g., PAR1), PAR4 exhibits delayed but sustained signaling, playing a unique role in cellular responses, particularly in platelets, immune cells, and vascular tissues. Its activation triggers pathways involving Gαq, Gα12/13. and β-arrestins, influencing processes like platelet aggregation, inflammation, and tissue repair.
PAR4 gained prominence due to its role in thrombosis. While PAR1 is a primary thrombin target in human platelets, PAR4 serves as a secondary activator, contributing to stable clot formation. This redundancy makes PAR4 a therapeutic target, especially in patients with PAR1 inhibitor resistance. Additionally, PAR4 is implicated in pathologies beyond hemostasis, including cancer progression, neuroinflammation, and cardiovascular diseases, highlighting its broad physiological impact.
Recombinant PAR4 proteins are engineered to study receptor-ligand interactions, signaling mechanisms, and drug development. Produced via heterologous expression systems (e.g., mammalian, insect, or bacterial cells), these proteins retain functional epitopes and post-translational modifications critical for activity. Researchers employ PAR4 recombinant proteins to screen antagonists, characterize antibodies, or map thrombin-binding domains.
Recent advances include PAR4-selective antagonists (e.g., BMS-986120) and monoclonal antibodies designed to inhibit pathological thrombosis without impairing hemostasis. Furthermore, PAR4 polymorphisms (e.g., rs773902) linked to altered receptor function underscore its clinical relevance in personalized medicine.
In summary, PAR4 recombinant proteins serve as vital tools for dissecting thromboinflammatory pathways and advancing targeted therapies, bridging molecular insights with translational applications.
×
